title: [Avastin a treatment of diabetic macular edema].
abstract: Macular edema is the first cause of visual impairment in diabetic patient. This paper is a retrospective evaluation of a group of patients with diabetic retinopathy and macular edema, treated with intravitreal Avastin (Bevacizumab) injection. The patients have been monitored mainly by assessing the evolution of visual acuity and macular thickness (OCT), after treatment, and the results have been compared with preexisting literature data.
authors.affiliation: Clinica Oftalmologică Cluj-Napoca.
authors.forename: Cristina
authors.initials: C
authors.lastname: Stan
authors.forename: Simona
authors.initials: S
authors.lastname: Sevan
authors.forename: Ioana
authors.initials: I
authors.lastname: Mureşan
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003930:Diabetic Retinopathy / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab